iRhythm Technologies saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 69 to 74.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating in the early stages of their moves. See if iRhythm Technologies can continue to rebound and hit that benchmark.
Can You Really Time The Stock Market?
While it's not currently an ideal time to buy shares, see if the stock goes on to form a base and break out.
iRhythm Technologies showed 0% EPS growth in its most recent report, while sales growth came in at 18%.
The company earns the No. 21 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!